
Join to view full profile
825 Eastlake Ave EMailstop CE2-112Seattle, WA 98109
Phone+1 206-606-7222
Dr. Bhatia is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shailender Bhatia is a medical oncologist in Seattle, WA and is affiliated with University of Washington (UW), and Fred Hutchinson Cancer Center (FHCC.) He serves as the Clinical and Clinical Research Director of the Melanoma and Renal Cancer Program at FHCC. Dr Bhatia received his medical degree from All India Institute of Medical Sciences (AIIMS) and subsequently completed hematology-oncology training at UW/FHCC. He has been practicing oncology for >15 years. He specializes in skin cancers (including melanoma and Merkel cell carcinoma) and has led numerous cutting-edge clinical trials of immunotherapy in skin cancers, many of which led to FDA-approval of new agents. He has more than 100 publications, which have over 20,000 citations.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ConnecticutResidency, Internal Medicine, 2001 - 2004
All India Institute of Medical SciencesClass of 2000
Certifications & Licensure
WA State Medical License 2004 - 2027
CT State Medical License 2004 - 2005
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma Start of enrollment: 2023 Nov 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Reprogramming the tumor microenvironment from within: intratumoral immunoadjuvants in cancer immunotherapy.Ai Phuong S Tong, Katrina Poljakov, Daniel D Lane, Grace Laidlaw, Wayne Monsky
Journal for Immunotherapy of Cancer. 2026-10-22 - Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast.Shailender Bhatia, Sandra D'Angelo, Paul Nghiem
Targeted Oncology. 2026-10-07 - Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Yuta Asano, Joshua R Veatch, Cheng-Jung Sung, Tzu-Hao Tang, Francesco Mazziotta
Science Translational Medicine. 2026-09-09
Press Mentions
Fred Hutch Phase 1 Program Director, Dr. John Thompson, RetiresDecember 19th, 2024
Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023
Merck Could Keep Its Patent Edge by Shifting Keytruda Cancer Drug to a Simple ShotDecember 2nd, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: